T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes.
about
Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcomaAnthrax toxin-mediated delivery in vivo and in vitro of a cytotoxic T-lymphocyte epitope from ovalbuminCross-presentation of tumour antigens: evaluation of threshold, duration, distribution and regulation.Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells.Advances in gene therapy for malignant melanoma.Doxorubicin-enriched, ALDH(br) mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.Therapeutic vaccination with tumor cells that engage CD137.Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation.Novel approaches to therapeutic cancer vaccines.Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapyCutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen.Clinical utilization of chemokines to combat cancer: the double-edged sword.Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapyIn vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo.Preclinical development of HIvax: Human survivin highly immunogenic vaccinesAdoptive transfer of cytotoxic T-cells for treatment of residual disease after irradiation.Efficient priming and expansion of antigen-specific CD8+ T cells by a novel cell-based artificial APC.Gene therapy by membrane-expressed superantigen for alpha-fetoprotein-producing hepatocellular carcinoma.Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy.Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs.Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB.Immunotherapy Targeting WT1: Designing a Protocol for WT1 Peptide-Based Cancer Vaccine.
P2860
Q24814867-DDF8767A-9F46-4AB1-BA95-7331712ED075Q33750314-7B4D8167-5295-41A5-B1D1-E99BA6306881Q33778847-DDCB292A-A71C-4AB4-BF22-87B262E4B3E5Q33896804-F766E058-C4F0-4B99-BFDD-A35D162E44ECQ34119859-E41FAE19-AE31-4970-9328-F1F8085CEDE6Q34486691-38CC3C4A-0893-4630-B033-F4E57AA422FBQ35064131-919E4C00-56F4-4E28-93B9-0441746A2A25Q35071688-0A1B5DB8-241A-4C65-A591-6E02B8CA8501Q35553621-37CA2F03-05A2-4214-A25F-6AC5350D38D3Q35623327-EF6979A4-E680-45CB-9EF3-12BFCAC5FD0DQ36380506-6B5FF67F-7101-42D7-89C8-17D0596B81CFQ36454472-083EDD24-B9FF-4FD4-B146-DCBB255B5449Q36473821-567A0139-C188-4930-863A-F2473739367EQ36488894-24C1012B-07A8-4B80-8B0E-B52ED60F383CQ36719911-6555E6A5-76BB-4C77-BE48-D574058D2B12Q37186903-E2D74405-1EE3-4A7C-AFEE-D607EF3AB67BQ37242580-74487A6A-868E-44B3-B2BC-DE639ED1D472Q38867680-C8307CB2-C6CE-4C29-8865-AB66C792A6F2Q40081629-8968E3EC-5BB3-4FE2-B1D5-0C75A1F31856Q40251310-12C46D0C-F638-432E-BE18-791B42EA7CFCQ40253340-D9A1825D-CB3D-48BA-9F42-680B2AA16B8CQ40360718-D8CF0B2B-5D91-4134-B613-561D84FE58DDQ40753339-EC98DC1D-435E-4137-B1E2-FD80EEEE937AQ45864659-2346FE7C-8625-4302-A1EB-F5373591A23EQ45884692-BB023800-922D-4044-B9D8-DF5413E4AE65Q51490182-A151FCD2-A836-490A-B1EB-F1E0D1D830FC
P2860
T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
T-cell immunotherapy of tumors ...... th minimal essential epitopes.
@en
type
label
T-cell immunotherapy of tumors ...... th minimal essential epitopes.
@en
prefLabel
T-cell immunotherapy of tumors ...... th minimal essential epitopes.
@en
P2860
P1476
T-cell immunotherapy of tumors ...... th minimal essential epitopes.
@en
P2093
P2860
P304
P356
10.1111/J.1600-065X.1995.TB00081.X
P577
1995-06-01T00:00:00Z